相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)
Jesus Feliu et al.
BONE MARROW TRANSPLANTATION (2020)
Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial
Merav Bar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report
Paul J. Martin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation for Pediatric Hematologic Malignancies
Biljana Horn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial
S. R. Solomon et al.
BONE MARROW TRANSPLANTATION (2014)
Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes
Pramila Krishnamurthy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Madan Jagasia et al.
BLOOD (2012)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure
Sajir G. Mohamedbhai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation
Eva Rettinger et al.
BLOOD (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Adam J. Mead et al.
BLOOD (2010)
Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse
Daniel J. Weisdorf et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
Koen van Besien et al.
LEUKEMIA & LYMPHOMA (2009)
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan
Akiko M. Saito et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation
Mohamad Mohty et al.
HAEMATOLOGICA (2007)
The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants
Bronwen E. Shaw et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
F Baron et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective
P Bader et al.
BONE MARROW TRANSPLANTATION (2004)
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
WA Bethge et al.
BLOOD (2004)
Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival
F Keil et al.
TRANSPLANTATION (2003)
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
BR Dey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2003)
T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation
J Mattsson et al.
TRANSPLANTATION (2001)
分享论文
